Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) benefited from strong short-term interest growth in October. As of October 29, there was short interest totaling 3,430,000 shares, an increase of 44.7% over the October 14 total of 2,370,000 shares. Based on an average daily volume of 1,880,000 shares, the short-term interest rate is currently 1.8 days. Currently 4.4% of the shares are sold short.

A number of institutional investors and hedge funds have recently changed their positions in the company. FMR LLC increased its stake in Maravai LifeSciences by 30.4% in the second quarter. FMR LLC now owns 12,652,271 shares of the company valued at $ 527,980,000 after purchasing an additional 2,949,028 shares during the period. Vanguard Group Inc. increased its stake in Maravai LifeSciences shares by 55.9% in the second quarter. Vanguard Group Inc. now owns 8,348,750 shares of the company valued at $ 348,393,000 after purchasing an additional 2,992,196 shares in the last quarter. Massachusetts Financial Services Co. MA increased its stake in Maravai LifeSciences shares by 10.4% in the third quarter. Massachusetts Financial Services Co. MA now owns 5,543,329 shares of the company valued at $ 272,067,000 after purchasing an additional 523,916 shares during the last quarter. JPMorgan Chase & Co. increased its stake in Maravai LifeSciences shares by 11.4% in the second quarter. JPMorgan Chase & Co. now owns 4,881,951 shares of the company valued at $ 203,724,000 after purchasing an additional 498,314 shares during the last quarter. Finally, BlackRock Inc. increased its stake in Maravai LifeSciences shares by 17.8% in the third quarter. BlackRock Inc. now owns 4,632,759 shares of the company valued at $ 227,377,000 after purchasing an additional 700,552 shares in the last quarter. Institutional investors and hedge funds hold 44.31% of the company’s shares.

A number of research analysts recently commented on the title. Morgan Stanley raised its price target for Maravai LifeSciences shares from $ 54.00 to $ 62.00 and rated the company as “overweight” in a research report released Thursday, August 12. KeyCorp raised its price target for Maravai LifeSciences shares from $ 46.00 to $ 58.00 and rated the stock “overweight” in a report released on Wednesday, August 11. Credit Suisse Group raised its price target for Maravai LifeSciences shares from $ 44.00 to $ 54.00 and gave the stock an “outperformance” rating in a report released on Wednesday, August 11. Robert W. Baird raised his price target for Maravai LifeSciences shares from $ 51.00 to $ 59.00 and gave the stock an “outperformance” rating in a report released on Wednesday, August 11. Finally, Zacks Investment Research downgraded Maravai LifeSciences shares from a “hold” rating to a “buy” rating and set a price target of $ 41.00 for the company in a research note on Saturday, November 13. . Eleven investment analysts rated the stock with a buy rating. According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $ 45.11.

NASDAQ MRVI shares opened at $ 37.62 on Friday. Maravai LifeSciences has a one-year low at $ 23.62 and a one-year high at $ 63.55. The company has a debt to equity ratio of 1.28, a current ratio of 6.01 and a quick ratio of 3.62. The company’s 50-day moving average is $ 42.32 and its 200-day moving average is $ 44.06. The stock has a market cap of $ 9.69 billion and a P / E ratio of 36.17.

Maravai LifeSciences (NASDAQ: MRVI) last reported its quarterly results on Wednesday, November 10. The company reported earnings per share (EPS) of $ 0.44 for the quarter, beating the consensus estimate of $ 0.35 by $ 0.09. Maravai LifeSciences had a net margin of 22.69% and a return on equity of 109.36%. The company posted revenue of $ 204.81 million for the quarter, compared to analysts’ expectations of $ 199.68 million. Research analysts predict that Maravai LifeSciences will post 1.51 earnings per share for the current year.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products for the development of drug therapies, diagnostics, new vaccines and supports research into human disease in the United States and around the world. The company’s products address key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products for detecting impurities in the production of biopharmaceuticals, and products for detecting expression. protein in tissues of various species.

Further Reading: What Does a Dividend Yield Mean for Investors?

This instant news alert was powered by narrative science technology and MarketBeat financial data to provide readers with the fastest, most accurate reports. This story was reviewed by the MarketBeat editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Should you invest $ 1,000 in Maravai LifeSciences now?

Before you consider Maravai LifeSciences, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated and top-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat identified the five stocks that top analysts are quietly asking their clients to buy now before the broader market takes hold of … and Maravai LifeSciences was not on the list.

While Maravai LifeSciences currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better bids.

See the 5 actions here